Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Tianqi Lithium (天齐锂业) IPO: Proceeds to Fund SQM Acquisition at Peak Pricing

Ganfeng Lithium Placement - Momentum Play

Ganfeng Lithium Placement - Recent Momentum Has Been Weakening, Last Deal Did Exceptionally Well

Ganfeng Lithium IPO (赣锋锂业): Falling Lithium Prices Weigh on the Leading Producer

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>Ganfeng Lithium was priced at the low end and it started trading last Thursday. It traded down by 23% on the first day but up 8% on the second day. In this post IPO note, we will have a look at the subscription results, the intraday trading. While the stock is trading at one of the deepest discounts to A-share (or highest A-H premium, this is in-line with the discount at pricing date. We wouldn't be buyers at these levels.</p>

Ganfeng Lithium was priced at the low end and it started trading last Thursday. It traded down by 23% on the first day but up 8% on the second day. In this post IPO note, we will have a look at the subscription results, the intraday trading. While the stock is trading at one of the deepest discounts to A-share (or highest A-H premium, this is in-line with the discount at pricing date. We wouldn't be buyers at these levels.

Ganfeng Lithium (赣锋锂业) Post IPO: Little Change to Discount to A-Share Despite Fall